Pharmala Biotech Holdings Inc

Pharmala Biotech licenses its lead drug ALA‑002 to Jupiter Neurosciences, securing over US$100 million and exclusive U.S. rights for a breakthrough psychedelic‑derived therapy.

Pharmala Biotech Holdings Inc. pushes oncology innovation, blending cutting‑edge R&D with strategic partnerships to deliver breakthrough cancer therapies despite market volatility.

Pharmala Biotech: Canadian oncology firm driving breakthrough cancer therapies and strong market growth through R&D innovation and strategic commercialization.

Pharmala Biotech eyes U.S. MDMA access, pivoting from oncology to psychiatric therapy amid FDA’s expanded‑access pathway—could boost growth or risk heavy costs.

Pharmala Biotech: navigating volatility while driving breakthrough oncology therapies—discover its R&D pipeline, partnerships, and growth strategy for next‑generation cancer treatment.

Pharmala Biotech Holdings Inc. drives oncology innovation with a strong IP portfolio, R&D focus, and strategic partnerships, aiming to transform cancer treatment despite market volatility.

Pharmala Biotech, a Canadian oncology‑focused biotech, blends R&D innovation with strategic partnerships to drive breakthrough cancer therapies and long‑term growth.

Pharmala Biotech’s fight against cancer: a Canadian firm’s resilient R&D, partnership strategy, and market risks revealed in its latest stock performance.

Pharmala Biotech Holdings Inc. is a Canadian biotech on the stock exchange, focused on oncology drug discovery and commercialization. With a 2026 market cap of CAD 11.4 M, a proprietary pipeline of cancer therapies and strategic partnerships, the co…

Pharmala Biotech’s latest press release reveals a key supply contract with Amsterdam UMC for its LaNeo MDMA platform, underscoring progress in oncology drug development.